The shadow of generic rivalry has long loomed over copyright’s famous drug, Viagra, triggering questions about the prospects of similar drug investments. While early years saw substantial gains, the intellectual property lapse has opened the door for cheaper alternatives, possibly reducing revenue and posing a significant risk for investors looki